Theranostics continue to gain momentum

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

Posição atual:
> This Story

Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment




More Magazine Features

The road ahead for breast density awareness It's been a good year for advocacy, here's what happens next

OB/GYN ultrasound: is the field ready to adopt new technology in the market? What do new capabilities mean for creatures of habit?

Breast imaging advances with new AI, MR and ultrasound solutions A look at innovative new technology entering the market

In nuclear medicine, scanners get more sensitive, software more specific What's new in PET and SPECT?

Installing and removing imaging equipment is no small task Expert insights on how project management is evolving

See All Magazine Features  

Molecular Imaging Homepage

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

Software innovations for patient-specific theranostics and molecular radiotherapy Trends that will impact the future of medicine

Philips shares insights on PET/CT utilization trends at SNMMI Continued growth in use expected through 2019

GE debuts Discovery IQ Gen 2 PET/CT system at SNMMI Equipped with MotionFree to prevent blurring of images

Rethinking training and education for the future of medicine at SNMMI Discussing innovations and efforts of SNMMI Technologist Section

SNMMI Product Showcase Don't miss these solutions on the exhibit floor

Mobile PET relieves hardship for rural cancer patients Mobile PET isn't just good medicine, it's good business

Theranostics continue to gain momentum

por John R. Fischer , Staff Reporter
From the June 2019 issue of DOTmed HealthCare Business News magazine

In more ways than one, 2018 was a year of expansion for Novartis International. In January the company completed its $3.9 billion acquisition of nuclear medicine company Advanced Accelerator Applications (AAA), and in October it completed the $2.1 billion purchase of biopharmaceutical enterprise, Endocyte.

But in addition to scaling its company footprint, the Swiss-based pharmaceutical provider expanded its stake in another area — the emerging and promising field of theranostics. With AAA providing it access to its neuroendocrine tumor treatment, 177-Lu-Lutathera, and Endocyte giving it the same for its prostate cancer drug, 177-Lu-PSMA-617.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

Interest in theranostics has driven a lot of business activity in recent years and energized not just companies but providers in nuclear medicine in working to develop radiotherapeutic molecules that can diagnose, determine a personalized course of action for, and treat various forms of cancer. The word itself is a portmanteau of diagnostics and therapeutics.

“The strong growth of radiotherapeutics represented around 14 percent of the total nuclear medicine market in 2018 - up from 3 percent in 2012 – and is expected to represent 60 percent, or even more, of the $26 billion U.S. nuclear medicine market by 2030,” Paul-Emmanuel Goethals, co-founder of MEDraysintell, a business intelligence firm specializing in nuclear medicine, told HCB News. “They are driving the growth of radiotheranostics, and their overall development along with that of conventional therapeutics will boost development of associated PET and SPECT tracers.”

Origins, and where it is today
Although the term was first coined in the 1990s, the concept of theranostics dates back to the 1940s when iodine was applied in both diagnostic imaging and therapy for benign and malignant thyroid tumors.

“You can give someone I-123, and using molecular imaging, you can see where the iodine goes and visualize metastatic thyroid cancer,” said Dr. Thomas Hope, a nuclear medicine physician and associate professor of radiology at the University of California, San Francisco. “Then, you can give them I-131, which has a different type of radiation emitted that can treat the thyroid cancer.”

This practice refers to a specific example of theranostics known as radiotheranostics. While in this scenario the same radionuclide is used for diagnosis and therapy, other forms of radiotheranostics involve different radionuclides paired together with a targeting ligand. One radionuclide is used to image the tumor, while the other is used to treat it.
  Pages: 1 - 2 - 3 - 4 >>

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment